Pyxis Oncology Launches Public Offering Of Common Stock/Pre-Funded Warrants And Warrants To Fund MICVO Phase 3 Development; No Terms Disclosed
Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a registered public offering (the
Pyxis Oncology is raising money by selling new stock to fund cancer drug testing. When companies do this, watch if the price drops and think about whether the company needs more cash than expected.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.